There is a 15-minute delay in the prices. To check out the live prices, log in to your Ventura account or open one today.
| Orders | Qty | Bid |
|---|---|---|
| 1 | 8 | 2492 |
| 1 | 20 | 2491.5 |
| 1 | 8 | 2491.3 |
| 3 | 64 | 2491 |
| 2 | 22 | 2490.8 |
| Ask | Qty | Orders |
|---|---|---|
| 2492.2 | 3 | 33 |
| 2492.3 | 1 | 14 |
| 2492.4 | 3 | 38 |
| 2492.7 | 1 | 1 |
| 2493 | 1 | 1 |
Annual Revenue,rose 15.73%, in the last year to ₹6,746.98 Cr. Its sector's average revenue growth for the last fiscal year was 12.14%.Annual Net Profit,rose 47.07% in the last year to ₹1,027.32 Cr. Its sector's average net profit growth for the last fiscal year was 2.16%.Price to Earning Ratio,is 39.32, lower than its sector PE ratio of 43.36.
Gland Pharma Limited is a Hyderabad-based global injectable manufacturer founded in 1978 by P.V.N. Raju. The company develops, manufactures and markets complex generic injectables across formats such as pre-filled syringes, vials (liquid and lyophilised), ampoules, bags and eye drops, backed by in-house API capabilities and a strong Contract Development and Manufacturing Organisation (CDMO) focus. Operations span over 60 countries, including the United States, Europe, Canada, Australia, New Zealand and India, supported by 11 plants across formulations and APIs.
The company operates primarily on a B2B model globally, complemented by a direct B2C presence in India; services include contract development, dossier compilation, technology transfer and manufacturing across delivery systems. As of March 31, 2025, Gland Pharma has 10 subsidiaries (including step-down subsidiaries) .
Key milestones include: incorporation in 1978; USFDA approval for the Dundigal facility (2003); launch of Enoxaparin Sodium Injection (Cutenox) in India and rest-of-world markets (2004–05); USFDA and EU approvals for the Oncology plant at Visakhapatnam SEZ (2014); commencement of US commercial sales from the Pashamylaram facility and multiple facility approvals (2016); majority stake acquisition by Fosun Singapore (2019); and the acquisition of Cenexi to strengthen the CDMO build-out (2023). During FY 2024–25, the company also highlighted additional production lines for newer formats such as ready-to-use products, sterile cartridges and specialty vials being installed and ready for commercial production .
– By business model (FY 2024–25 revenue mix):
– B2B – IP-led (Own ANDA): 33%
– B2B – IP-led (Partner ANDA): 25 Per cent
– B2B – Tech Transfer: 41%
– B2C – India: 1%
– By markets (FY 2024–25 revenue mix):
– USA: 54%; Europe: 19%; India: 4%; Canada: 2%; Australia: 2%; Rest of World: 19%.
– Srinivas Sadu – Executive Chairman
– Shyamakant Giri – Chief Executive Officer
– Ravi Shekhar Mitra – Chief Financial Officer
– P. Sampath Kumar – Company Secretary
– Regulatory: The Dundigal and Pashamylaram facilities received Establishment Inspection Reports (EIRs) from the USFDA during the year, underscoring a strong compliance track record .
– Capacity and technology: New lines for suspensions, hormonal products, peptides and microspheres have been installed; additional production lines for ready-to-use products, sterile cartridges, pre-filled syringes, dry powder and liquid vials, bulk cartridges and specialty vials were readied for commercial production .
– Strategic collaborations: The company advanced its foray into complex CDMO and biologies, including a long-term collaboration with Dr. Reddy’s Laboratories at its biologies facility in Genome Valley, Hyderabad, and collaboration with Shanghai Henlius Biotech for biosimilar manufacturing; it is also focusing on GLP-1 products, with two CDMO contracts onboarded .
– International footprint: Integration of Cenexi, a European CDMO with expertise in sterile liquid and lyophilised fill-finish formulations including oncology, continued to enhance Gland’s overseas manufacturing presence and CDMO offerings in Europe .
The all-time high (ATH) for Gland Pharma Ltd was ₹4,316.25, recorded on 12 Aug 2021. At the current price of ₹2,449.00, the stock is trading 43.26% below its all-time high. The all-time low recorded was ₹893.55 on 22 May 2023.
No,Gland Pharma Ltd has not declared any dividend over the past 5 years. The company paid a total dividend of 58.00 per share between FY2022 and FY2026, with the most recent dividend of ₹20.00 per share for May 26, with an ex-dividend date of 11 Aug 2026. At the current market price of ₹2,449.00, the trailing dividend yield of Gland Pharma Ltd stands at 38.00%.
Gland Pharma Ltd has delivered a return of 36.46% over the last 3 months. The stock was trading at ₹1,797.40 on 17 Apr 2026 and is currently at ₹2,449.00 as of 18 Jul 2026, reflecting a Gain of ₹651.60 per share over this period.
The intraday high for Gland Pharma Ltd on the NSE today (18 Jul 2026) was ₹2,564.80. This compares to the 52-week high of ₹2,573.50 recorded on 08 Jul 2026. Today's high was -0.34% below the 52-week high.
Gland Pharma Ltd has delivered 22.43% return over the last 52 weeks. During this period, the stock hit a 52-week high of ₹2,573.50 on 08 Jul 2026 and a 52-week low of ₹1,573.60 on 16 Mar 2026. It is currently trading at ₹2,449.00 as of 18 Jul 2026.
For Q4 FY26, Gland Pharma Ltd reported: Revenue (Net Sales): ₹12615.92 Cr - Up 7.14% year-on-year from ₹11775.13 Cr in Q3 FY26. Net Income (PAT): ₹4204.51 Cr - Up 36.58% year-on-year from ₹3078.47 Cr in Q3 FY26.
Gland Pharma Ltd has delivered a -36.53% absolute return over the past 5 years, equivalent to a CAGR of -8.69% per annum. The stock was priced at ₹3,858.52 in Jul 2021 and has fallen to ₹2,449.00 as of 18 Jul 2026. An investment of ₹1,00,000 in Gland Pharma Ltd five years ago would be worth ₹63,470.00 today.
As of 18 Jul 2026, the share price of Gland Pharma Ltd is ₹2,449.00 on the NSE and ₹2,449.90 on the BSE. The stock opened at ₹2,509.00, touched a high of ₹2,564.80 and a low of ₹2,435.00 during today's session.
Over the last 6 months, Gland Pharma Ltd has given a return of 45.70%. The stock was priced at ₹1,680.90 on 19 Jan 2026 and has Rise to ₹2,449.00 as of 18 Jul 2026, a change of ₹768.10 per share.
The intraday low for Gland Pharma Ltd on the NSE today was ₹2,435.00. The stock's 52-week low stands at ₹1,573.60, recorded on 16 Mar 2026. Today's low is 54.74% above the 52-week low, indicating the stock is trading well above its yearly lows.
